Latest Breaking News On - Maha ha hussain - Page 1 : comparemela.com

Piecing the Puzzle Together: Treatment After Progression in Metastatic Castration-Resistant Prostate Cancer

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution.

United statesNew yorkMaha ha hussainDepartment of medicineNorthwestern university feinberg school of medicineDivision of hematologyInterdisciplinary prostate cancer congressRoberth lurie comprehensive cancer centerGu oncology programAnnual interdisciplinary prostate cancer congressEducation resourceComprehensive cancer centerNorthwestern universityFeinberg schoolTurn after antiandrogens run theirCancers symposium

Triplet therapy effective for metastatic prostate cancer subset regardless of disease volume

Treatment intensification with darolutamide plus androgen deprivation therapy and docetaxel improved OS among men with metastatic hormone-sensitive prostate cancer regardless of disease volume or risk, according to study results.The benefits of early treatment intensification appeared consistent among men with high-volume or low-volume disease, as well as those with high-risk or low-risk disease,

Byashley killenMark leiserMaha ha hussainAstellas pharmaCancers symposiumClinical oncologyComprehensive cancer centerNorthwestern university feinberg schoolHemonc today editorial board

PROfound: Phase 3 Study of Olaparib vs Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations

PROfound: Phase 3 Study of Olaparib vs Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoNobuaki matsubaraMaha ha hussainFred saadAntoine thiery vuilleminKim chiKarim fizaziJoaquin mateoSelena castroKimn chiOlaparib lynparzaEuropean multidisciplinary congress on urological cancersAmerican urologic associationVirtual annual meetingJohann de bono

ASCO GU 2023: Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study

ASCO GU 2023: Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

United statesNorthwestern universitySan franciscoMaha ha hussainFred saadMartin boegemannKarim fizaziMaha hussainFrank verholenShankar srinivasanBertrandf tombalIris kussShivani kapurHeikki joensuuArash rezazadehE david crawford

Second look analysing prostate cancer study data reaps new rewards

Dr Maha Hussain at the recent virtual ASCO Meeting. Credit: ASCO Second look analysing prostate cancer study data reaps new rewards Two studies unveiled at last month’s virtual Genitourinary Cancers Symposium, organised by the American Society of Clinical Oncology, will have implications for both the treatment of prostate cancer and the provision of screening, Peter Doyle reports In men with non-metastatic castration-resistant prostate cancer (nmCRPC) and rapidly rising prostate specific antigen (PSA) treated with androgen deprivation therapy (ADT) plus enzalutamide (ENZA), there was a close relationship between the degree of PSA decline and survival outcomes, according to a newly published post-hoc analysis of the PROSPER trial.

United statesMaha ha hussainVidit sharmaRobert dreicerPeter doyleUs preventive services task forceUniversity of california los angelesAmerican society of clinical oncologyAmerican association of central cancer registriesGenitourinary cancers symposiumAmerican societyClinical oncologyEfficacy studyServices task forceNorth american associationCentral cancer registries